ZEO ScientifiX Financials
This page shows ZEO ScientifiX (ZEOX) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
High gross margins are being overwhelmed by a fixed overhead structure that still runs ahead of the company’s revenue base.
From FY2023 to FY2025, operating cash burn shrank from-$2.2M to-$718K , a much bigger improvement than the income statement alone suggests. Because net losses still remained near-$5.5M in FY2025 while capex was only$23K , the business became less cash-hungry before it became profitable, which points to an overhead problem rather than a capital-intensive one.
Gross margin stayed above
Negative equity shows accumulated losses still outweigh the asset base, but the balance sheet did get less strained as total liabilities fell from
Financial Health Signals
We are recalculating ZEO ScientifiX's peer-relative financial health score against the latest fiscal year. It will appear here once the refresh completes. The signals and metrics below are current.
ZEO ScientifiX scores -40.02, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($12.9M) relative to total liabilities ($3.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
ZEO ScientifiX passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.
For every $1 of reported earnings, ZEO ScientifiX generates $0.13 in operating cash flow (-$718K OCF vs -$5.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
ZEO ScientifiX earns $-55.0 in operating income for every $1 of interest expense (-$5.4M vs $98K). This narrow margin raises concern about the company's ability to service its debt if operating income declines.
Key Financial Metrics
Earnings & Revenue
ZEO ScientifiX generated $5.2M in revenue in fiscal year 2025. This represents an increase of 12.5% from the prior year.
ZEO ScientifiX's EBITDA was -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.3% from the prior year.
ZEO ScientifiX reported -$5.5M in net income in fiscal year 2025. This represents a decrease of 17.3% from the prior year.
ZEO ScientifiX earned $-0.86 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 16.2% from the prior year.
Cash & Balance Sheet
ZEO ScientifiX generated -$741K in free cash flow in fiscal year 2025, representing cash available after capex.
ZEO ScientifiX held $1.0M in cash against $0 in long-term debt as of fiscal year 2025.
ZEO ScientifiX had 8M shares outstanding in fiscal year 2025. This represents an increase of 20.0% from the prior year.
Margins & Returns
ZEO ScientifiX's gross margin was 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the prior year.
ZEO ScientifiX's operating margin was -103.6% in fiscal year 2025, reflecting core business profitability. This is up 11.5 percentage points from the prior year.
ZEO ScientifiX's net profit margin was -106.2% in fiscal year 2025, showing the share of revenue converted to profit. This is down 4.4 percentage points from the prior year.
Capital Allocation
ZEO ScientifiX invested $100K in research and development in fiscal year 2025. This represents a decrease of 39.0% from the prior year.
ZEO ScientifiX invested $23K in capex in fiscal year 2025, funding long-term assets and infrastructure.
ZEOX Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6M+78.5% | $1.4M-12.6% | $1.7M+26.6% | $1.3M+13.7% | $1.1M+5.4% | $1.1M-12.4% | $1.2M+14.0% | $1.1M |
| Cost of Revenue | $526K+87.2% | $281K+9.8% | $256K+12.3% | $228K-10.9% | $256K+34.0% | $191K-15.1% | $225K+27.8% | $176K |
| Gross Profit | $2.1M+76.4% | $1.2M-16.7% | $1.4M+29.7% | $1.1M+20.7% | $893K-0.7% | $899K-11.8% | $1.0M+11.4% | $915K |
| R&D Expenses | $31K+63.2% | $19K | N/A | N/A | $42K+600.0% | $6K-89.5% | $57K-24.0% | $75K |
| SG&A Expenses | $2.6M+25.6% | $2.0M-1.1% | $2.1M-34.4% | $3.1M+37.7% | $2.3M+6.3% | $2.2M-11.9% | $2.4M+17.3% | $2.1M |
| Operating Income | -$512K+41.7% | -$878K-31.4% | -$668K+67.7% | -$2.1M-48.6% | -$1.4M-11.3% | -$1.3M+12.1% | -$1.4M-22.0% | -$1.2M |
| Interest Expense | $11K+10.0% | $10K-68.8% | $32K+39.1% | $23K+9.5% | $21K-4.5% | $22K0.0% | $22K-4.3% | $23K |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$145K+83.0% | -$852K-4.5% | -$815K+60.7% | -$2.1M-49.0% | -$1.4M-11.9% | -$1.2M+0.9% | -$1.3M-23.9% | -$1.0M |
| EPS (Diluted) | $-0.02+83.3% | $-0.12 | N/A | $-0.32-45.5% | $-0.22-10.0% | $-0.20 | N/A | $-0.16 |
ZEOX Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $3.9M+51.1% | $2.6M+68.4% | $1.5M-7.6% | $1.7M+15.1% | $1.4M-7.4% | $1.6M-5.7% | $1.6M-26.0% | $2.2M |
| Current Assets | $3.3M+62.7% | $2.0M+109.5% | $958K-9.9% | $1.1M+22.9% | $865K-20.6% | $1.1M-6.4% | $1.2M-32.5% | $1.7M |
| Cash & Equivalents | $1.8M+79.2% | $1.0M+366.1% | $221K-29.6% | $314K-42.1% | $542K-24.7% | $720K+9.6% | $657K-40.5% | $1.1M |
| Inventory | $686K+36.7% | $502K+18.7% | $423K+64.0% | $258K+9.8% | $235K-4.1% | $245K+5.6% | $232K-7.2% | $250K |
| Accounts Receivable | $276K+338.1% | $63K+80.0% | $35K | N/A | $11K+83.3% | $6K-96.9% | $194K+921.1% | $19K |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.2M+7.4% | $3.0M+0.1% | $3.0M-25.6% | $4.0M+12.2% | $3.5M+5.4% | $3.4M+1.8% | $3.3M-9.5% | $3.6M |
| Current Liabilities | $3.1M+7.8% | $2.9M+0.5% | $2.9M-25.9% | $3.9M+12.2% | $3.5M+3.1% | $3.3M+1.9% | $3.3M-9.5% | $3.6M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $51K |
| Total Equity | $712K+285.9% | -$383K+73.1% | -$1.4M+38.5% | -$2.3M-10.2% | -$2.1M-16.3% | -$1.8M-9.2% | -$1.7M-16.2% | -$1.4M |
| Retained Earnings | -$68.7M-0.2% | -$68.6M-1.3% | -$67.7M-1.2% | -$66.9M-3.2% | -$64.8M-2.2% | -$63.5M-2.0% | -$62.2M-2.1% | -$61.0M |
ZEOX Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$138K+70.7% | -$471K-23.0% | -$383K-49.0% | -$257K-79.7% | -$143K-320.0% | $65K+117.8% | -$366K-289.4% | -$94K |
| Capital Expenditures | $64K+357.1% | $14K | $0 | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | -$202K+58.4% | -$485K-26.6% | -$383K | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $312K+2328.6% | -$14K | $0 | N/A | N/A | N/A | $0 | N/A |
| Financing Cash Flow | $642K-50.4% | $1.3M+346.2% | $290K+457.7% | $52K+248.6% | -$35K-1650.0% | -$2K+97.6% | -$82K-116.5% | $498K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ZEOX Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 79.6%-0.9pp | 80.6%-3.9pp | 84.5%+2.0pp | 82.5%+4.8pp | 77.7%-4.8pp | 82.5%+0.6pp | 81.9%-2.0pp | 83.9% |
| Operating Margin | -19.8%+40.9pp | -60.7%-20.3pp | -40.4%+118.2pp | -158.6%-37.3pp | -121.3%-6.4pp | -115.0%-0.4pp | -114.5%-7.5pp | -107.1% |
| Net Margin | -5.6%+53.3pp | -58.9%-9.6pp | -49.3%+109.4pp | -158.7%-37.6pp | -121.1%-7.0pp | -114.0%-13.2pp | -100.8%-8.0pp | -92.8% |
| Return on Equity | -20.4% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -3.7%+29.4pp | -33.1%+20.2pp | -53.4%+72.0pp | -125.4%-28.5pp | -96.9%-16.7pp | -80.2%-3.9pp | -76.3%-30.8pp | -45.6% |
| Current Ratio | 1.05+0.4 | 0.70+0.4 | 0.33+0.1 | 0.27+0.0 | 0.25-0.1 | 0.33-0.0 | 0.35-0.1 | 0.47 |
| Debt-to-Equity | 4.46 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| FCF Margin | -7.8%+25.7pp | -33.5%-10.4pp | -23.2% | N/A | N/A | N/A | N/A | N/A |
Note: Shareholder equity is negative (-$383K), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Note: The current ratio is below 1.0 (0.70), indicating current liabilities exceed current assets, which may suggest potential short-term liquidity concerns.
Similar Companies
Frequently Asked Questions
What is ZEO ScientifiX's annual revenue?
ZEO ScientifiX (ZEOX) reported $5.2M in total revenue for fiscal year 2025. This represents a 12.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is ZEO ScientifiX's revenue growing?
ZEO ScientifiX (ZEOX) revenue grew by 12.5% year-over-year, from $4.6M to $5.2M in fiscal year 2025.
Is ZEO ScientifiX profitable?
No, ZEO ScientifiX (ZEOX) reported a net income of -$5.5M in fiscal year 2025, with a net profit margin of -106.2%.
What is ZEO ScientifiX's EBITDA?
ZEO ScientifiX (ZEOX) had EBITDA of -$5.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is ZEO ScientifiX's gross margin?
ZEO ScientifiX (ZEOX) had a gross margin of 82.1% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is ZEO ScientifiX's operating margin?
ZEO ScientifiX (ZEOX) had an operating margin of -103.6% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is ZEO ScientifiX's net profit margin?
ZEO ScientifiX (ZEOX) had a net profit margin of -106.2% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is ZEO ScientifiX's free cash flow?
ZEO ScientifiX (ZEOX) generated -$741K in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is ZEO ScientifiX's operating cash flow?
ZEO ScientifiX (ZEOX) generated -$718K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are ZEO ScientifiX's total assets?
ZEO ScientifiX (ZEOX) had $2.6M in total assets as of fiscal year 2025, including both current and long-term assets.
What are ZEO ScientifiX's capital expenditures?
ZEO ScientifiX (ZEOX) invested $23K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does ZEO ScientifiX spend on research and development?
ZEO ScientifiX (ZEOX) invested $100K in research and development during fiscal year 2025.
What is ZEO ScientifiX's current ratio?
ZEO ScientifiX (ZEOX) had a current ratio of 0.70 as of fiscal year 2025, which is below 1.0, which may suggest potential liquidity concerns.
What is ZEO ScientifiX's return on assets (ROA)?
ZEO ScientifiX (ZEOX) had a return on assets of -214.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is ZEO ScientifiX's cash runway?
Based on fiscal year 2025 data, ZEO ScientifiX (ZEOX) had $1.0M in cash against an annual operating cash burn of $718K. This gives an estimated cash runway of approximately 17 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
Why is ZEO ScientifiX's debt-to-equity ratio negative or not reported?
ZEO ScientifiX (ZEOX) has negative shareholder equity of -$383K as of fiscal year 2025, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is ZEO ScientifiX's Altman Z-Score?
ZEO ScientifiX (ZEOX) has an Altman Z-Score of -40.02, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is ZEO ScientifiX's Piotroski F-Score?
ZEO ScientifiX (ZEOX) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are ZEO ScientifiX's earnings high quality?
ZEO ScientifiX (ZEOX) has an earnings quality ratio of 0.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
Can ZEO ScientifiX cover its interest payments?
ZEO ScientifiX (ZEOX) has an interest coverage ratio of -55.0x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.